Myriad Genetics
MYGN
About: Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
Employees: 2,700
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
2,234% more call options, than puts
Call options by funds: $2.45M | Put options by funds: $105K
72% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 53
4% less funds holding
Funds holding: 228 [Q1] → 219 (-9) [Q2]
4.74% less ownership
Funds ownership: 102.91% [Q1] → 98.18% (-4.74%) [Q2]
14% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 49
42% less capital invested
Capital invested by funds: $833M [Q1] → $481M (-$353M) [Q2]
Financial journalist opinion
Based on 8 articles about MYGN published over the past 30 days
